Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
Fierce Biotech11d
Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Fierce Pharma4d
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Yahoo Finance4d
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
Merck reported adjusted earnings of $1.72 per ... charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15.62 ...
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
CNN on MSN13d
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
AOL26d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Merck is one of the largest pharmaceutical ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a potential cancer ...